Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of zanubrutinib in B-cell malignancies
2024-511267-28-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of zanubrutinib in B-cell malignancy, sponsored by BeOne Medicines. Primary endpoint: Safety. Planned start Feb 2021; status: authorised.
02
Drugs
zanubrutinib
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on 2024-511267-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511267-28-00.